Các con đường tín hiệu liên quan đến lncRNA MALAT1 trong u xương Osteosarcoma

Lindsey BA, Markel JE, Kleinerman ES. Osteosarcoma overview. Rheumatol Ther. 2017;4:25–43. Le Nail L-R, Brennan M, Rosset P, Deschaseaux F, Piloquet P, Pichon O, Le Caignec C, Crenn V, Layrolle P, Hérault O, De Pinieux G, Trichet V. Comparison of tumor- and bone marrow-derived mesenchymal stromal/stem cells from patients with high-grade osteosarcoma. Int J Mol Sci. 2018;19:707. Soeharno H, Povegliano L, Choong PF. Multimodal treatment of bone metastasis-a surgical perspective. Front Endocrinol (Lausanne). 2018;9:518–518. Fernandes I, Melo-Alvim C, Lopes-Brás R, Esperança-Martins M, Costa L. Osteosarcoma pathogenesis leads the way to new target treatments. Int J Mol Sci. 2021;22:813. Ferrari S, Serra M. An update on chemotherapy for osteosarcoma. Expert Opin Pharmacother. 2015;16:2727–36. Eaton BR, Schwarz R, Vatner R, Yeh B, Claude L, Indelicato DJ, Laack N. Osteosarcoma. Pediatr Blood Cancer. 2020;68:e28352. Meazza C, Bastoni S, Scanagatta P. What is the best clinical approach to recurrent/refractory osteosarcoma? Expert Rev Anticancer Ther. 2020;20:415–28. Ramezanpour S, Horvai A E, Piawah S, Link T M, Primary osteosarcoma of the parietal bone. Skeletal Radiology 2021: 1–5. Desai SA, Manjappa A, Khulbe P. Drug delivery nanocarriers and recent advances ventured to improve therapeutic efficacy against osteosarcoma: an overview. J Egypt Natl Canc Inst. 2021;33:1–14. Tung F-I, Zheng L-J, Hou K-T, Chiang C-S, Chen M-H, Liu T-Y. One-stop radiotherapeutic targeting of primary and distant osteosarcoma to inhibit cancer progression and metastasis using 2DG-grafted graphene quantum dots. Nanoscale. 2020;12:8809–18. Iwata S. Osteosarcoma metastasis—prognostic factors and treatment strategies. In: Introduction to cancer metastasis. Netherlands: Elsevier; 2017. p. 223–32. Raimondi L, De Luca A, Costa V, Amodio N, Carina V, Bellavia D, Tassone P, Pagani S, Fini M, Alessandro R, Giavaresi G. Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment. Oncotarget. 2017;8:100831–51. Letafati A, Najafi S, Mottahedi M, Karimzadeh M, Shahini A, Garousi S, Abbasi-Kolli M, Sadri Nahand J, Tamehri Zadeh SS, Hamblin MR, Rahimian N, Taghizadieh M, Mirzaei H. MicroRNA let-7 and viral infections: focus on mechanisms of action. Cell Mol Biol Lett. 2022;27:14. Rothzerg E, Pfaff AL, Koks S. Innovative approaches for treatment of osteosarcoma. Exp Biol Med. 2022;247:310–16. Kong C, Hansen MF. Biomarkers in osteosarcoma. Expert Opin Med Diagn. 2009;3:13–23. Otoukesh B, Boddouhi B, Moghtadaei M, Kaghazian P, Kaghazian M. Novel molecular insights and new therapeutic strategies in osteosarcoma. Cancer Cell Int. 2018;18:158. Sayles LC, Breese MR, Koehne AL, Leung SG, Lee AG, Liu H-Y, Spillinger A, Shah AT, Tanasa B, Straessler K. Genome-informed targeted therapy for osteosarcoma. Cancer Discov. 2019;9:46–63. Landuzzi L, Manara MC, Lollini P-L, Scotlandi K. Patient derived xenografts for genome-driven therapy of osteosarcoma. Cells. 2021;10:416. Liu M, Yang P, Mao G, Deng J, Peng G, Ning X, Yang H, Sun H. Long non-coding RNA MALAT1 as a valuable biomarker for prognosis in osteosarcoma: a systematic review and meta-analysis. Int J Surg. 2019;72:206–13. Anbiyaiee A, Ramazii M, Bajestani SS, Meybodi SM, Keivan M, Khoshnam SE, Farzaneh M. The function of LncRNA-ATB in cancer. Clin Transl Oncol. 2022. https://doi.org/10.1007/s12094-022-02848-1. Xu W-W, Jin J, Wu X-y, Ren Q-L, Farzaneh M. MALAT1-related signaling pathways in colorectal cancer. Cancer Cell Int. 2022;22:1–9. Min L, Garbutt C, Tu C, Hornicek F, Duan Z. Potentials of long noncoding RNAs (lncRNAs) in sarcoma: from biomarkers to therapeutic targets. Int J Mol Sci. 2017;18:731. Yang Z, Li X, Yang Y, He Z, Qu X, Zhang Y. Long noncoding RNAs in the progression, metastasis, and prognosis of osteosarcoma. Cell Death Dis. 2016;7:e2389–e2389. Alishahi M, Ghaedrahmati F, Kolagar TA, Winlow W, Nikkar N, Farzaneh M, Khoshnam SE. Long non-coding RNAs and cell death following ischemic stroke. Metab Brain Dis. 2019;34:1243–51. Smolle MA, Pichler M. The role of long non-coding RNAs in osteosarcoma. Noncoding RNA. 2018;4:7. Sun XH, Yang LB, Geng XL, Wang R, Zhang ZC. Increased expression of lncRNA HULC indicates a poor prognosis and promotes cell metastasis in osteosarcoma. Int J Clin Exp Pathol. 2015;8:2994–3000. Najafi S, Ghafouri-Fard S, Hussen BM, Jamal HH, Taheri M, Hallajnejad M. Oncogenic roles of small nucleolar RNA host gene 7 (SNHG7) long noncoding RNA in human cancers and potentials. Front Cell Dev Biol. 2022;9:809345. Han Z, Shi L. Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis. Biochem Biophys Res Commun. 2018;495:947–53. Ghafouri-Fard S, Najafi S, Hussen BM, Ganjo AR, Taheri M, Samadian M. DLX6-AS1: a long non-coding RNA with oncogenic features. Front Cell Dev Biol. 2022;10:746443. Chen F, Mo J, Zhang L. Long noncoding RNA BCAR4 promotes osteosarcoma progression through activating GLI2-dependent gene transcription. Tumour biol J Int Soc Oncodevelopmental Biol Med. 2016;37:13403–12. Liu M, Yang P, Mao G, Deng J, Peng G, Ning X, Yang H, Sun H. Long non-coding RNA MALAT1 as a valuable biomarker for prognosis in osteosarcoma: a systematic review and meta-analysis. Int J surg (London, England). 2019;72:206–13. Hanly DJ, Esteller M, Berdasco M. Interplay between long non-coding RNAs and epigenetic machinery: emerging targets in cancer? Philos Trans R Soc Lond B Biol Sci. 2018;373:20170074. Qian Y, Shi L, Luo Z. Long non-coding RNAs in cancer: implications for diagnosis, prognosis, and therapy. Front Med (Lausanne). 2020;7:612393–612393. Sun Y, Ma L. New insights into long non-coding RNA MALAT1 in cancer and metastasis. Cancers (Basel). 2019;11:216. Li Z, Dou P, Liu T, He S. Application of long noncoding RNAs in osteosarcoma: biomarkers and therapeutic targets. Cell Physiol Biochem. 2017;42:1407–19. Kim J, Piao H-L, Kim B-J, Yao F, Han Z, Wang Y, Xiao Z, Siverly AN, Lawhon SE, Ton BN. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet. 2018;50:1705–15. Zhao L, Lou G, Li A, Liu Y. lncRNA MALAT1 modulates cancer stem cell properties of liver cancer cells by regulating YAP1 expression via miR-375 sponging. Mol Med Rep. 2020;22:1449–57. Wang Y, Zhang Y, Yang T, Zhao W, Wang N, Li P, Zeng X, Zhang W. Long non-coding RNA MALAT1 for promoting metastasis and proliferation by acting as a ceRNA of miR-144-3p in osteosarcoma cells. Oncotarget. 2017;8:59417–34. Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, Tassone P. MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. J Hematol Oncol. 2018;11:63–63. Zhang Z-C, Tang C, Dong Y, Zhang J, Yuan T, Tao S-C, Li X-L. Targeting the long noncoding RNA MALAT1 blocks the pro-angiogenic effects of osteosarcoma and suppresses tumour growth. Int J Biol Sci. 2017;13:1398–408. Liu B, Zhan X, Liu C. Long noncoding RNA MALAT1 interacts with miR-124-3p to modulate osteosarcoma progression by targeting SphK1. J Oncol. 2021;2021:8390165. Zhang Z-C, Tang C, Dong Y, Zhang J, Yuan T, Li X-L. Targeting LncRNA-MALAT1 suppresses the progression of osteosarcoma by altering the expression and localization of β-catenin. J Cancer. 2018;9:71–80. Duan G, Zhang C, Xu C, Xu C, Zhang L, Zhang Y. Knockdown of MALAT1 inhibits osteosarcoma progression via regulating the miR-34a/cyclin D1 axis. Int J Oncol. 2019;54:17–28. Liu B, Zhan X, Liu C. Long noncoding RNA MALAT1 interacts with miR-124-3p to modulate osteosarcoma progression by targeting SphK1. J Oncol 2021; 2021:8390165. Zhang Y, Dai Q, Zeng F, Liu H. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the Rac1/JNK pathway via targeting MiR-509. Oncol Res Featur Preclin Clin Cancer Ther 2021;7:1–12. Malakoti F, Targhazeh N, Karimzadeh H, Mohammadi E, Asadi M, Asemi Z, Alemi F. The multiple function of lncRNA MALAT1 in cancer occurrence and progression. Chem Biol Drug Des. 2021. https://doi.org/10.1111/cbdd.14006. Arun G, Aggarwal D, Spector DL. MALAT1 long non-coding RNA: functional implications. Non-coding RNA. 2020;6:22. Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E. MALAT-1, a novel noncoding RNA, and thymosin β 4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22:8031–41. Sun Q, Hao Q, Prasanth KV. Nuclear long noncoding RNAs: key regulators of gene expression. Trends Genet. 2018;34:142–57. Wilusz JE, JnBaptiste CK, Lu LY, Kuhn C-D, Joshua-Tor L, Sharp PA. A triple helix stabilizes the 3’ ends of long noncoding RNAs that lack poly(A) tails. Genes Dev. 2012;26:2392–407. Yang F, Yi F, Han X, Du Q, Liang Z. MALAT-1 interacts with hnRNP C in cell cycle regulation. FEBS Lett. 2013;587:3175–81. Wang X, Sehgal L, Jain N, Khashab T, Mathur R, Samaniego F. LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2. J Transl Med. 2016;14:1–14. Gholami A, Farhadi K, Sayyadipour F, Soleimani M, Saba F. Long noncoding RNAs (lncRNAs) in human lymphomas. Genes Dis. 2021;9:900–14. Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X, Zhang Y, Gorospe M, Prasanth SG, Lal A, Prasanth KV. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet. 2013;9:e1003368–e1003368. Liu P, Yang H, Zhang J, Peng X, Lu Z, Tong W, Chen J. The lncRNA MALAT1 acts as a competing endogenous RNA to regulate KRAS expression by sponging miR-217 in pancreatic ductal adenocarcinoma. Sci Rep. 2017;7:5186. Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339:159–66. Zhang Y-F, Li C-S, Zhou Y, Lu X-H. Propofol facilitates cisplatin sensitivity via lncRNA MALAT1/miR-30e/ATG5 axis through suppressing autophagy in gastric cancer. Life Sci. 2020;244: 117280. Lu X, Chen D, Yang F, Xing N. Quercetin inhibits epithelial-to-mesenchymal transition (EMT) process and promotes apoptosis in prostate cancer via downregulating lncRNA MALAT1. Cancer Manag Res. 2020;12:1741. Paronetto MP, Dimauro I, Grazioli E, Palombo R, Guidotti F, Fantini C, Sgrò P, De Francesco D, Di Luigi L, Capranica L. Exercise-mediated downregulation of MALAT1 expression and implications in primary and secondary cancer prevention. Free Radical Biol Med. 2020;160:28–39. Peng N, He J, Li J, Huang H, Huang W, Liao Y, Zhu S. Long noncoding RNA MALAT1 inhibits the apoptosis and autophagy of hepatocellular carcinoma cell by targeting the microRNA-146a/PI3K/Akt/mTOR axis. Cancer Cell Int. 2020;20:1–11. Li Z-X, Zhu Q-N, Zhang H-B, Hu Y, Wang G, Zhu Y-S. MALAT1: a potential biomarker in cancer. Cancer Manag Res. 2018;10:6757. Liang J, Liang L, Ouyang K, Li Z, Yi X. MALAT 1 induces tongue cancer cells’ EMT and inhibits apoptosis through Wnt/β-catenin signaling pathway. J Oral Pathol Med. 2017;46:98–105. Dong Y, Liang G, Yuan B, Yang C, Gao R, Zhou X. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. Tumor Biol. 2015;36:1477–86. Yang Z-m, Yang M-f, Yu W, Tao H-m. Molecular mechanisms of estrogen receptor β-induced apoptosis and autophagy in tumors: implication for treating osteosarcoma. J Int Med Res. 2019;47:4644–55. Fang D, Yang H, Lin J, Teng Y, Jiang Y, Chen J, Li Y. 17β-Estradiol regulates cell proliferation, colony formation, migration, invasion and promotes apoptosis by upregulating miR-9 and thus degrades MALAT-1 in osteosarcoma cell MG-63 in an estrogen receptor-independent manner. Biochem Biophys Res Commun. 2015;457:500–6. Ren D, Zheng H, Fei S, Zhao JL. MALAT1 induces osteosarcoma progression by targeting miR-206/CDK9 axis. J Cell Physiol. 2019;234:950–7. Luo W, He H, Xiao W, Liu Q, Deng Z, Lu Y, Wang Q, Zheng Q, Li Y. MALAT1 promotes osteosarcoma development by targeting TGFA via MIR376A. Oncotarget. 2016;7:54733–43. Zhang J, Piao C-D, Ding J, Li Z-W. LncRNA MALAT1 facilitates lung metastasis of osteosarcomas through miR-202 sponging. Sci Rep. 2020;10:12757. Li Q, Pan X, Wang X, Jiao X, Zheng J, Li Z, Huo Y. Long noncoding RNA MALAT1 promotes cell proliferation through suppressing miR-205 and promoting SMAD4 expression in osteosarcoma. Oncotarget. 2017;8: 106648. Wei L, Surma M, Shi S, Lambert-Cheatham N, Shi J. Novel insights into the roles of Rho kinase in cancer. Arch Immunol Ther Exp. 2016;64:259–78. Guan H, Tan P, Xie L, Mi B, Fang Z, Li J, Yue J, Liao H, Li F. FOXO1 inhibits osteosarcoma oncogenesis via Wnt/β-catenin pathway suppression. Oncogenesis. 2015;4: e166. Wang J, Sun G. FOXO1-MALAT1-miR-26a-5p Feedback loop mediates proliferation and migration in osteosarcoma cells. Oncol Res Featur Preclin Clin Cancer Ther. 2017;25:1517–27. Tripathi A, Shrinet K, Kumar A. HMGB1 protein as a novel target for cancer. Toxicol Rep. 2019;6:253–61. Liu K, Huang J, Ni J, Song D, Ding M, Wang J, Huang X, Li W. MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142–3p and miR-129–5p. Cell Cycle. 2017;16:578–87. Wang P, Wang Z, Liu J. Role of HDACs in normal and malignant hematopoiesis. Mol Cancer. 2020;19:5. Sun Y, Qin B. Long noncoding RNA MALAT1 regulates HDAC4-mediated proliferation and apoptosis via decoying of miR-140-5p in osteosarcoma cells. Cancer Med. 2018;7:4584–97. Takahashi M, Kawai K, Asai N. Roles of the RET proto-oncogene in cancer and development. JMA J. 2020;3:175–81. Chen Y, Huang W, Sun W, Zheng B, Wang C, Luo Z, Wang J, Yan W. LncRNA MALAT1 promotes cancer metastasis in osteosarcoma via activation of the PI3K-Akt signaling pathway. Cell Physiol Biochem. 2018;51:1313–26. Liu K, Zhang Y, Liu L, Yuan Q. MALAT1 promotes proliferation, migration, and invasion of MG63 cells by upregulation of TGIF2 via negatively regulating miR-129. Onco Targets Ther. 2018;11:8729–40. Sun Z, Zhang T, Chen B. Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) promotes proliferation and metastasis of osteosarcoma cells by targeting c-Met and SOX4 via miR-34a/c-5p and miR-449a/b. Med Sci Monit. 2019;25:1410–22. Wang Q, Liu M-J, Bu J, Deng J-L, Jiang B-Y, Jiang L-D, He X-J. miR-485-3p regulated by MALAT1 inhibits osteosarcoma glycolysis and metastasis by directly suppressing c-MET and AKT3/mTOR signalling. Life Sci. 2021;268: 118925. Hosokawa Y, Arnold A. Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression. Genes Chromosom Cancer. 1998;22:66–71. Sa-Nguanraksa D, O-Charoenrat P. The role of vascular endothelial growth factor a polymorphisms in breast cancer. Int J Mol Sci. 2012;13:14845–64. Vimalraj S, Subramanian R, Dhanasekaran A. LncRNA MALAT1 promotes tumor angiogenesis by regulating microRNA-150-5p/VEGFA signaling in osteosarcoma: in-vitro and in-vivo analyses. Front Oncol. 2021;11:742789–742789. Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK, Giles FJ. Wnt/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol. 2017;10:101. Jung Y-S, Park J-I. Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex. Exp Mol Med. 2020;52:183–91. Li F, Chen X, Shang C, Ying Q, Zhou X, Zhu R, Lu H, Hao X, Dong Q, Jiang Z. Bone marrow mesenchymal stem cells-derived extracellular vesicles promote proliferation, invasion and migration of osteosarcoma cells via the lncRNA MALAT1/miR-143/NRSN2/Wnt/β-catenin axis. Onco Targets Ther. 2021;14:737–49. Chen Q, Xie J, Yang Y. Long non-coding RNA NRSN2-AS1 facilitates tumorigenesis and progression of ovarian cancer via miR-744-5p/PRKX axis. Biol Reprod. 2022;106:526–39. Da M, Zhuang J, Zhou Y, Qi Q, Han S. Role of long noncoding RNA taurine-upregulated gene 1 in cancers. Mol Med. 2021;27:51. Chiappetta C, Leopizzi M, Censi F, Puggioni C, Petrozza V, Rocca CD, Di Cristofano C. Correlation of the Rac1/RhoA pathway with ezrin expression in osteosarcoma. Appl Immunohistochem Mol Morphol. 2014;22:162–70. Archibald A, Mihai C, Macara IG, McCaffrey L. Oncogenic suppression of apoptosis uncovers a Rac1/JNK proliferation pathway activated by loss of Par3. Oncogene. 2015;34:3199–206. Yao C, Ruan J-W, Zhu Y-R, Liu F, Wu H-M, Zhang Y, Jiang Q. The therapeutic value of the SphK1-targeting microRNA-3677 in human osteosarcoma cells. Aging (Albany NY). 2020;12:5399. Cai Q, Zhao X, Wang Y, Li S, Wang J, Xin Z, Li F. LINC01614 promotes osteosarcoma progression via miR-520a-3p/SNX3 axis. Cell Signal. 2021;83: 109985. Liu C, Han X, Li B, Huang S, Zhou Z, Wang Z, Wang W. MALAT-1 is associated with the doxorubicin resistance in U-2OS osteosarcoma cells. Cancer Manag Res. 2021;13:6879–89. de Azevedo JWV, de Fernandes TAAM, Fernandes JV, de Azevedo JCV, Lanza DCF, Bezerra CM, Andrade VS, de Araujo JMG. Biology and pathogenesis of human osteosarcoma. Oncol lett. 2020;19:1099–116. Zhao M, Wang S, Li Q, Ji Q, Guo P, Liu X. MALAT1: a long non-coding RNA highly associated with human cancers. Oncol Lett. 2018;16:19–26.